Inflation devices for intragastric devices with improved attachment and detachment and associated systems and methods

Information

  • Patent Grant
  • 9629740
  • Patent Number
    9,629,740
  • Date Filed
    Wednesday, April 6, 2011
    13 years ago
  • Date Issued
    Tuesday, April 25, 2017
    7 years ago
Abstract
Inflation devices for inflating intragastric devices and associated systems and methods are disclosed herein. In several embodiments, an inflation device can include a tube, an inner detent, and an outer detent. The tube can extend from a proximal portion of the inflation device to a distal portion of the inflation device, and can include a handle at the proximal portion and a barb at the distal portion. The barb can have a cross-sectional dimension greater than a cross-sectional dimension of a corresponding inflation port of an intragastric device. The inner detent can be positioned over the barb and can include a mating interface. The outer detent can be positioned over the inner detent, and can be configured to attach over a proximal cap of the intragastric device. The tube can be longitudinally advanceable relative to at least one of the inner and outer detents.
Description
TECHNICAL FIELD

The present technology relates generally to implantable gastric devices. In particular, the present technology relates to inflation devices for implanting and inflating an intragastric device in situ and associated systems and methods.


BACKGROUND

Implantable gastric devices can occupy a volume within a patient's stomach to decrease the available room for food. This creates a feeling of satiety that can control the patient's appetite and cause weight loss. Intragastric balloons, for example, can be filled with a biocompatible fluid (e.g., saline solution) and left within the stomach for an extended period of time to treat obesity and/or other weight related conditions. Implanting such an intragastric balloon generally includes inserting the deflated balloon through the patient's mouth or nose with a filler tube or catheter, and inflating the balloon in situ. The intragastric balloon can eventually be removed by deflating the balloon, grasping it with an extraction tool, and removing the intragastric balloon via the esophagus and mouth.


A challenge associated with the inflation of intragastric balloons is that conventional inflation tools can inadvertently disconnect from the intragastric balloons during insertion and/or inflation. However, if it is difficult to disconnect the intragastric balloon from the inflation tools, the extra force (e.g., tugging) necessary for disengagement can agitate or impose trauma on the stomach wall. Thus, there is a need to improve the inflation of intragastric devices.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic isometric view of an intragastric device in accordance with an embodiment of the present technology.



FIG. 2 is a schematic top view of the intragastric device of FIG. 1.



FIG. 3 is a schematic cross-sectional view of the intragastric device taken substantially along the line 3-3 of FIG. 2.



FIG. 4 is a schematic cross-sectional view of the intragastric device taken along line 4-4 of FIG. 2.



FIG. 5 is a top view of a proximal portion of an inflation device in accordance with an embodiment of the present technology.



FIG. 6 is a top view of a proximal portion of an intragastric device and a distal portion of the inflation device of FIG. 5.



FIG. 7 is a cut-away view of an inflation device engaged with an intragastric device in accordance with an embodiment of the present technology.



FIG. 8 is a cut-away view of an inflation device and an intragastric device in accordance with another embodiment of the present technology.



FIGS. 9-12 are cut-away views of the inflation device of FIG. 8 in various stages of engagement with the intragastric device in accordance with embodiments of the present technology.



FIG. 13 is a side elevational view of an inflation assembly in accordance with an embodiment of the present technology.





DETAILED DESCRIPTION

Specific details of several embodiments of the present technology are described below with reference to an inflation device for an intragastric device and associated methods for inflating, implanting, and explanting such devices. Although many of the embodiments are described below with respect to a dual balloon intragastric device, other embodiments of intragastric devices can include only one balloon or more than two balloons. Moreover, several further embodiments of the technology can have different configurations, components, or procedures than those described in this section. A person of ordinary skill in the art, therefore, will accordingly understand that the technology may have other embodiments with additional elements, or the technology may have other embodiments without several of the features shown and described below with reference to FIGS. 1-13.


The terms “distal” and “proximal” within this application reference a relative position of portions of an intragastric device and/or an inflation device with reference to an operator. Proximal refers to a position closer to the operator of the device, and distal refers to a position that is more distant from the operator of the device.



FIG. 1 is an isometric view of an intragastric device 10 in accordance with an embodiment of the present technology, and FIG. 2 is a top view of the intragastric device 10 of FIG. 1. The intragastric device 10 may include at least one expandable, space-filling component, such as a balloon 30. As shown in FIG. 1, the intragastric device 10 can include a first balloon 30a and a second balloon 30b fixed to a shaft 20. In other embodiments, the intragastric device 10 can include additional balloons 30. As shown in FIGS. 1 and 2, the intragastric device 10 may also include or be configured to interface with a proximal cap 200 at a proximal portion 150a of the intragastric device 10.



FIG. 3 is a cross-sectional view of the intragastric device 10 taken substantially along the line 3-3 of FIG. 2. As shown in FIG. 3, the shaft 20 of the intragastric device 10 may include a plurality of lumens 40 (identified individually as a first lumen 40a and a second lumen 40b), each corresponding to a balloon 30 of the intragastric device 10. For example, the first lumen 40a may provide fluid communication from a first inflation port 47a to an interior portion of the first balloon 30a via a first inflation opening 32a. Likewise, the second lumen 40b may provide fluid communication from a second inflation port 47b to an interior portion of the second balloon 30b via a second inflation opening 33b.


Each lumen 40 may have a corresponding inflation port 47 at a proximal end thereof. The inflation ports 47 may be configured to allow infusion of fluids into corresponding lumens 40 and inhibit or prevent the exit of fluids from the same. The inflation ports 47 may include check valves, clack valves, non-return valves, one-way valves, duckbill valves, reed valves, flapper valves, etc. For example, the first inflation port 47a may be provided at a proximal end of the first lumen 40a. Likewise, the second inflation port 47b may be provided at a proximal end of the second lumen 40b.


As shown in FIG. 3, each lumen 40 of the shaft 20 may be divided into inflation chambers 42 (identified individually as a first inflation chamber 42a and a second inflation chamber 43b) and aspiration chambers (identified individually as a first aspiration chamber 44a and a second aspiration chamber 44b). For example, the first lumen 40a may be divided into the first inflation chamber 42a and the first aspiration chamber 44a by a first barrier 46a. Similarly, the second lumen 40b may be divided into the second inflation chamber 43b and the second aspiration chamber 44b by a second barrier 46b. Such barriers 46 may partition the lumens 40 into at least two separate chambers that may be fluidly connected via the interior portion of a corresponding balloon 30.


Each balloon 30 may have an opening that fluidly connects the interior portion of the balloon 30 with at least a portion of the corresponding lumen 40. As shown in FIG. 3, each balloon 30 can have a plurality of openings that connect the interior portion of the balloon 30 with disparate chambers (e.g., the inflation chambers 42, the aspiration chambers 44) of the corresponding lumen 40. For example, a first inflation opening 32a may provide a fluid connection between the interior of the first balloon 30a and the first inflation chamber 42a, and a first aspiration opening 34a may provide a fluid connection between the interior of the first balloon 30a and the first aspiration chamber 44a. Similarly, a second inflation opening 33b may provide a fluid connection between the interior of the second balloon 30b and the second inflation chamber 43b, and a second aspiration opening 34b may provide a fluid connection between the interior of the second balloon 30b and the second aspiration chamber 44b.


As further shown in FIG. 3, the intragastric device 10 can include sleeves 50 (identified individually as a first sleeve 50a and a second sleeve 50b) within the interior of the balloons 30 that cover the inflation openings 32. Such sleeves 50 may allow inflation of the balloon from the corresponding inflation opening 32 while inhibiting or preventing deflation through the same opening 32. The sleeves 50 may wrap radially around the portion of the shaft 20 with compression force near the corresponding opening 32. For example, the first sleeve 50a may be provided within the interior portion of the first balloon 30a and cover at least the first inflation opening 32a. Similarly, the second sleeve 50b may be provided within the interior portion of the second balloon 30b and cover at least the second inflation opening 33b. The sleeve 50 may inhibit or prevent undesirable fluid passage through the inflation openings 32, and thereby reduce fluid leakage from inflated balloons 30 and associated issues. For example, when pressure within the balloon 30 exceeds pressure in the corresponding inflation chamber 42, the sleeve 50 may be pressed with radial compression against the corresponding inflation opening 32 to inhibit or prevent leakage into the lumen 40. When pressure within the inflation chamber 42 exceeds pressure within the corresponding balloon 30, the sleeve 50 may separate from the corresponding inflation opening 32 and permit fluid passage through the inflation opening 32 into the balloon 30.


Additionally, as shown in FIG. 3, each lumen 40 may have a corresponding aspiration port 48 (identified individually as a first aspiration port 48a and a second aspiration port 48b) formed by the opening at the distal end thereof. The aspiration ports 48 may be selectively covered by a sealing device 100. For example, the first aspiration port 48a may be at a distal end of the first lumen 40a. Similarly, the second aspiration port 48b may be provided at a distal end of the second lumen 40b.



FIG. 4 is a cross-sectional view of the intragastric device 10 taken substantially along the line 4-4 of FIG. 2. In the illustrated embodiment, a guidewire channel 112 may extend through the sealing device 100, the proximal cap 200, and the shaft 20 of the intragastric device 10. The guidewire channel 112 may be configured to accommodate a guidewire for assisted delivery and management of the intragastric device 10 during implant, explant, or maintenance thereof.



FIG. 5 is a top view of a proximal portion 350 of an inflation device 300 in accordance with an embodiment of the present technology. The inflation device 300 may be provided for delivery and inflation of the intragastric device 10 (FIGS. 1-4) in situ. As shown in FIG. 5, at a proximal portion 350a, the inflation device 300 may include tubes 310 (identified individually as a first tube 310a and a second tube 310b) corresponding to each balloon 30 of the intragastric device 10. For example, the first tube 310a may mechanically and fluidly connect a first handle 330a to a first barb 320a (FIG. 7), and the second tube 310b may mechanically and fluidly connect a second handle 330b to a second barb 320b (FIG. 7). Longitudinal advancement and retraction of the first barb 320a and the second barb 320b may be actuated by a user operating the first handle 330a and the second handle 330b at the proximal portion 350a of the inflation device 300. As further shown in FIG. 5, the tubes 310 can be enclosed, contained, and/or otherwise stored at least partially within a housing 312. In other embodiments, the inflation device 300 does not include the housing 312.



FIG. 6 is a top view of the proximal portion 150 of the intragastric device 10 of FIGS. 1-4 and the distal portion 350b of the inflation device 300 of FIG. 5. As shown in FIG. 6, the distal portion 350b of the inflation device 300 may be configured to mate with the proximal cap 200 of the intragastric device 10. Advancement, retraction, and positioning of barbs 320 (FIG. 7) may be sensed by a user holding a corresponding handle 330. Inflation of at least one of the first balloon 30a and the second balloon 30b can occur while the inflation device 300 is mated with the proximal cap 200 of the intragastric device 10.



FIG. 7 is a cut-away view of the inflation device 300 of FIGS. 5 and 6 engaged with the intragastric device 10 of FIGS. 1-4 in accordance with an embodiment of the present technology. As shown in FIG. 7, the inflation device 300 may include at least one of an outer detent 302 and an inner detent 304. The outer detent 302 and the inner detent 304 may be separate pieces or separate portions of the same integral piece. The outer detent 302 may mate around or over a distal portion (e.g., flared/flanged section) of the proximal cap 200. In selected embodiments, the outer detent 302 can be elastic such that the outer detent 302 can shrink when removed from the proximal cap 200 for a lower safety profile. In other embodiments, the outer detent 302 can be rigid or non-elastic (e.g., a fiber hoop) and configured to collapse. Whether elastic or non-elastic, the large outer detent 302 provides retention forces and stability that is generally higher than an internal fixed flange of a smaller diameter (e.g., as with a flanged attachment of the BIB device). Additionally, when collapsed, the outer detent 302 takes up less space in the esophagus to enable simultaneous retraction of both an associated catheter and scope, or serial retraction of both components.


The inner detent 304 may mate against a proximal portion of the proximal cap 200. Before, during, or after such mating, the first barb 320a may be inserted into the first inflation port 47a to provide fluid to the first lumen 40a, and the second barb 320b may be inserted into the second inflation port 47b to provide fluid to the second lumen 40b. In the embodiment illustrated in FIG. 7, the mating interface 390 is a flat surface. In other embodiments, the mating interface 390 can include ridges, beveled edges, filleted edges, and/or other non-planar surfaces.


As shown in FIG. 7, the first barb 320a and the second barb 320b may be longitudinally advanceable relative to at least one of the outer detent 302 and the inner detent 304. At least a portion of the first barb 320a and/or the second barb 320b may have a diameter or cross-sectional area that exceeds the diameter or cross-sectional area of at least a portion of the corresponding inflation port 47 in an unengaged state. Accordingly, insertion of the first barb 320a into the first inflation port 47a or the second barb 320b into the second inflation port 47b may cause expansion of the proximal cap 200 in an engaged state. As indicated by the arrows in FIG. 7, the expansion of the proximal cap 200 may be radially outward. The proximal cap 200 can also expand in other directions (e.g., toward the inner detent 304). Such expansion may reduce the ease with which the outer detent 302 may disengage from the proximal cap 200. For example, engaging the outer detent 302 around the proximal cap 200 may be made more secure by the expansion of the proximal cap 200 such that the force required to disengage the outer detent 302 from the proximal cap 200 is greater when one or both of the barbs 320 are engaged within the corresponding inflation port 47. Accordingly, the force required to disengage the outer detent 302 from the proximal cap 200 is lower when one or both of the barbs 320 are disengaged from the corresponding inflation ports 47.



FIG. 8 is a cut-away view of an inflation device 800 and the intragastric device 10 in accordance with another embodiment of the present technology. The inflation device 800 includes features generally similar to the inflation device 300 described above with reference to FIGS. 5-7. For example, the inflation device 800 can include the tubes 310 connected to the barbs 320, the outer detent 302, and the inner detent 304. The inner detent 304 can also include the mating interface 390. As shown in FIG. 8, the mating interface 390 can be configured to leave an open space 391 near the proximal cap 200 when the inflation device 800 and the proximal cap 200 are engaged. The open space 391 can be defined by the mating interface 390 and the proximal cap 200. For example, in the embodiment illustrated in FIG. 8, the open space 391 is defined by a chamfered portion 393 of the mating interface 390 and the proximal cap 200. In other embodiments, the mating interface 390 can include scallops, ridges, and/or other cut-outs with different shapes and geometries that leave one or more open spaces 391 near the proximal cap 200.


The open space 391 may provide a channel into which the proximal cap 200 may expand. For example, insertion of at least one of the barbs 320 into the corresponding inflation ports 47 may cause expansion of the proximal cap 200. At least some of the expansion of the proximal cap 200 may occur into the open space 391 rather than against the outer detent 302. The distribution of this expansion may increase the force required to disengage the outer detent 302 from the proximal cap 200, further allowing the proximal cap material to deflect when the barbs 320 are retracted. This allows a user to selectively reduce the engagement force of the outer 302 detent to the proximal cap 200.



FIGS. 9-12 show the inflation device 800 of FIG. 8 in various stages of inserting the barbs 320 into the inflation ports 47 of the intragastric device 10. Referring to FIGS. 9-12 together, the intragastric device 10 may achieve an engaged state relative to inflation device 800. The outer detent 302 may be mated around a distal portion of the proximal cap 200, and the inner detent 304 may be mated against a proximal portion of the proximal cap 200. As shown in FIGS. 9 and 10, the first barb 320a and the second barb 320b may be mated within the corresponding first and second inflation ports 47a-b. In the engaged state, as shown in FIG. 10, the proximal cap 200 may expand due at least to the insertion of the barbs 320 into the corresponding inflation ports 47. The expansion of the proximal cap 200 may be against the outer detent 302, the inner detent 304, or the open space 391 defined by at least mating interface 390 and proximal cap 200.


In selected embodiments, engaging the intragastric device 10 with the inflation device 800 may be performed in situ within a gastric cavity of a patient. For example, the inflation device 800 may be attached to an intragastric device 10 that was previously deployed within the gastric cavity.


In other embodiments, engaging the intragastric device 10 with the inflation device 800 may be performed before insertion into a patient. For example, the intragastric device 10 and the inflation device 800 may be provided together in an engaged state or as a part of a kit of parts. Directions for use may further be provided. In the engaged state, the outer detent 302 may be mated around to a distal portion of the proximal cap 200, the inner detent 304 may be mated against a proximal portion of the proximal cap 200, and the first barb 320a and the second barb 320b may be mated within the first inflation port 47a and the second inflation port 47b, respectively. In the engaged state, the proximal cap 200 may be expanded.


The engaged intragastric device 10 and the inflation device 800 may be delivered to a gastric cavity. A fluid may be flowed to intragastric device 10. For example, the fluid may flow through at least one of the first handle 330a, the first tube 310a, the first barb 320a, the first inflation port 47a, the first inflation chamber 42a, the first inflation opening 32a, and the first balloon 30a. Similarly, the fluid may flow through at least one of the second handle 330b, the second tube 310b, the second barb 320b, the second inflation port 47b, the second inflation chamber 43b, the second inflation opening 33b, and the second balloon 30b. As such, at least one of the first balloon 30a and the second balloon 30b may be inflated to a desired volume.


In selected embodiments, the first balloon 30a and the second balloon 30b may be inflated simultaneously. Similarly, any number of balloons 30 may be inflated simultaneously corresponding to the number of separate inflation structures (e.g., handles 330, tubes 310, barbs 340, inflation ports 47, inflation chambers 42, and inflation openings 32). A plurality of inflation structures may reduce the total amount of time required to inflate the balloons 30 of intragastric device 10 by a factor corresponding to the number of inflation structures. For example, where N number of inflation structures are provided, the amount of time required to inflate the balloons 30 of the intragastric device 10 may be reduced by a factor of N. Additionally, because each balloon 30 includes at least one corresponding inflation structure, there is no need to attach a barb 320 to one inflation port 47, inflate, detach, and repeat the process with another inflation port 47.


As shown in FIGS. 11 and 12, at least one of the first barb 320a and the second barb 320b may be retracted and removed from the corresponding inflation port 47. The open space 391 can facilitate withdrawal of the barbs 320 as it allows silicone material from the proximal cap 200 a place to go during barb withdrawal. In selected embodiments, a user may feel tactile feedback as each barb 320 moves out of the proximal cap 200. A user may also hear an audible feedback when the barb stops against the inner detent 304 if such a stop is provided, especially when the barb 320 stops against the inner detent 304. Accordingly, the proximal cap 200 may contract due to the removal of at least one of the first barb 320a and the second barb 320b. Such contraction may result in lower forces applied by the proximal cap 200 on the outer detent 302 or the inner detent 304. Therefore, the force required to disengage the outer detent 302 and/or the inner detent 304 from the proximal cap 200 may be reduced once the proximal cap 200 has contracted.


To disengage and separate the inflation device 800 from the intragastric device, the outer detent 302 may be removed from around the proximal cap 200 and the inner detent 304 may be removed from against the proximal cap 200. In selected embodiments, such separation of the inflation device 800 from the intragastric device 10 can result from the application of lateral forces. For example, the inflation device 800 may be advanced against the inflated gastric device 10, causing it to distort or rotate. The distorted shape or rotation of intragastric device 10 may cause a lateral force to be applied at the engagement location of the intragastric device 10 and the inflation device 800, causing it to buckle at the engagement location. Such forces may exceed the forces maintaining engagement. As described above, the forces maintaining engagement can be reduced after removal of the first barb 320a and/or the second barb 320b or by the mating interface 390. The reduction of this force may likewise reduce the force placed on the gastric wall supporting such actions. The body of the inflation device 800 may provide an opposing force to retract the barbs 320 such that the inserted barbs 320 do not exceed engagement forces, but with the removed barbs 320 it does exceed engagement forces. This allows for secure placement as well as very little to no pull force on removal of the inflation device 800.


In other embodiments, the inflation device 800 may be separated from the intragastric device 10 by opposing forces. A tension force may be provided by retracting the inflation device 800 at a second end thereof. An opposing force against the intragastric device 10 may be provided by the gastroesophageal junction. The junction may provide such a force after the balloon(s) 30 of intragastric device 10 are inflated such that a diameter thereof exceeds the diameter of the gastroesophageal junction. When force is applied from the gastroesophageal junction, it is inherent that a substantially equal tensile force applies to the engagement location of the inflation device 800. Reduction of the force required to disengage inflation device 800 from intragastric device 10 may be beneficial in that the force applied to and from the gastroesophageal junction is reduced. Accordingly, trauma to the gastroesophageal junction is likewise reduced.


In further embodiments, a force may be applied to the intragastric device 10 from another device that holds the intragastric device 10 in place relative to the retraction of the inflation device 800. For example, a rigid or partially rigid structure may hold the intragastric device 10 in place while the inflation device 800 is retracted.



FIG. 13 is a side elevational view of a proximal portion of an inflation assembly 1300 in accordance with an embodiment of the present technology. The inflation assembly 1300 can be coupled to the inflation devices 300 and 800 described above, and can be used to inject or otherwise introduce fluid into the intragastric device 10 (FIGS. 1-4). For example, FIG. 13 shows one of the tubes 310 at the proximal portion 350a of the intragastric device 300 or 800 coupled to a connector 1302 of the inflation assembly 1300. The connector 1302 can place a syringe and/or other fluid injection device 1304 in fluid communication with the tube 310. In the illustrated embodiment, for example, the connector 1302 is a Y-connector. In other embodiments, inflation assembly 1300 can include other suitable connectors 1302 that join the fluid injection device 1304 with the tubes 310. In operation, the fluid injection device 1304 can receive fluids and introduce them to the intragastric device 10 through the tubes 310. In selected embodiments, the fluid injection device 1304 can be used to introduce specific fluids into the balloons 30, such as mineral oils, antimicrobial agents, and/or other desired fluids or materials. The fillant fluid can be introduced into the balloons 30 through the fluid injection device 1304 and/or from a different site in fluid communication with the tubes 310. For example, as shown in FIG. 13, a fluid line 1308 (e.g., an IV line) can connect to one or more containers (e.g., a saline bag) that store the desired quantity of fluid for each balloon 30.


As further shown in FIG. 13, the inflation assembly 1300 can include one or more valves 1306 (identified individually as a first valve 1306a and a second valve 1306b) that regulate the direction of the fluid. For example, the valves 1306 can be one-way check valves to prevent backflow of the fluid as it enters the inflation assembly 1300. In the embodiments illustrated in FIG. 13, the first valve 1306a is positioned in line with the tubes 310 and the second valve 1306b is positioned in line with the fluid injection device 1304 to prevent backflow from each site of fluid entry. In other embodiments, one or more other valves 1306 can be included in the inflation assembly 1300 to regulate fluid entry and/or exit.


Additionally, the inflation assembly 1300, the inflation devices 300 and 800, and/or the intragastric device 10 described above can include features that reduce or prevent the mitigation of bacteria into the intragastric device 10 during or after implantation, inflation, deflation, and/or removal procedures. For example, the inflation assembly 1300 and the intragastric device 10 can include features that prevent bacteria from entering the balloons 30, and/or prevent bacteria from growing inside the balloons 30 during and after implantation. These features can prevent detrimental expansion of the balloons 30 caused by bacterial growth and its by-products (e.g., gas), reduce the likelihood of infection, and/or otherwise decrease failure of the intragastric device 10.


In selected embodiments, for example, components of the intragastric device 10, the inflation devices 300 and 800, the inflation assembly 1300, and/or associated devices (e.g., the delivery catheter, secondary inflation lines, syringes, containers, etc.) can be sterilized. The individual components of the inflation assembly 1300, the intragastric device 10, and/or other related tools and devices may be stored within a sterile kit as individual sterilized components. A sterile area or field can be used for set-up, implantation, and/or removal of the intragastric device 10. For example, associated devices can be attached to the inflation devices 300 and 800 on a sterile device tray, card, and/or other sterile working space before implantation. This sterile field can be packaged with the inflation devices 300 and 800, intragastric device 10, and/or inflation assembly 1300. Additionally, a cover (e.g., a hood, a cap) can encase connection sites (e.g., lures), the handles 330, related injection lines, fluid insertion containers 1304, and/or other components before implantation of the intragastric device 10. These covers can maintain the sanitation of the inflation devices 300 and 800, intragastric device 10, the inflation assembly 1300, and/or associated devices during implantation and inflation procedures. For example, covers can be pre-attached to portions (e.g., connection sites) of the inflation devices 300 and 800, intragastric device 10, and/or the inflation assembly 1300, such that the covered portion remains sanitized.


In other embodiments, the intragastric device 10, the inflation devices 300 and 800, the inflation assembly 1300, and/or portions thereof can be pre-attached before implantation such that the joined components can be sterilized together. For example, the inflation assembly 1300 can be pre-attached to the tubes 310. As another example, the inflation devices 300 and 800 can be pre-attached to the intragastric device 10.


In further embodiments, the inflation devices 300 and 800, the intragastric device 10, and/or associated devices can be comprised at least partially of materials with anti-microbial agents or other anti-bacterial features. The balloons 30, for example, can be made from a diphenyl loaded material. Additionally, the balloons 30 can be pressurized to reduce bacteria ingress.


The balloons 30 can also be filled with bacteriostatic fillants to prevent bacteria from growing within the balloons 30. For example, a sterile 0.9% sodium chloride solution bacteriostatic may be used as a fillant. Bacteriostatic agents can also be incorporated directly into the fillant. In selected embodiments, a bacteriostatic sealant, such as mineral oil with preservatives (e.g., tacophenol) can be used to kill expected bio-burden within the balloons 30.


In further embodiments, the inflation devices 300 and 800, the intragastric device 10, and/or other associated delivery and inflation devices can include other features to limit bacterial growth within the balloons 30. In selected embodiments, bacterial food sources can be reduced or eliminated. For example, powdered food sources (e.g. corn starch) on the intragastric device 10 and/or the inflation devices 300 and 800 may be replaced with sodium bicarbonate that is a less accessible carbon food source and creates a pH environment that is not favorable for some intragastric microbes. In other embodiments, a surface treatment (e.g., silicone dispersion) may be applied to interior portions of the balloons 30 to fill open pores in the balloon material. Lubricants (e.g., mineral oil) can also be injected inside the balloons 30 to fill porous portions. Inert and/or bacteriostatic dusting powder (e.g., zinc oxide, amoxicillin, barium sulfate, etc) can also be used within or over the balloons 30.


From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the technology. For example, the intragastric device 10 shown in FIGS. 1-4 includes two balloons and the inflation devices 300 and 800 of FIGS. 5-12 include two corresponding inflation lines. However, other embodiments can include multiple inflation lines for individual balloons 30 to decrease inflation time. Certain aspects of the new technology described in the context of particular embodiments may be combined or eliminated in other embodiments. For example, the intragastric devices described above include balloons, but the intragastric devices can include other inflatable, elastic space-fillers. Additionally, the methods of engaging and separating the inflation device 800 from the intragastric device 300 described above with reference to FIGS. 8-12 can similarly apply to the inflation device 300 of FIG. 7. Further, while advantages associated with certain embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.

Claims
  • 1. A system, comprising: an intragastric device including an inflatable balloon, a proximal cap having a flanged section, and an inflation port at a proximal portion of the intragastric device; andan inflation device comprising— an outer detent at a distal portion of the inflation device configured to connect over the proximal cap of the intragastric device;an inner detent having a mating interface; andat least one tube fluidly connecting a handle at a proximal portion of the inflation device to a barb at the distal portion of the inflation device, the barb having a cross-sectional dimension greater than a cross-sectional dimension of the inflation port of the intragastric device when the inflation port is unengaged from the barb, wherein the barb is configured to expand the proximal cap when the barb is inserted into the inflation port such that the flanged section of the proximal cap expands into the outer detent.
  • 2. The system of claim 1 wherein the barb is configured to mate within the inflation port of the intragastric device.
  • 3. The system of claim 2 wherein the inflation port is fluidly connected to the inflatable balloon of the intragastric device.
  • 4. The system of claim 1 wherein the barb is longitudinally advanceable relative to at least one of the outer detent and the inner detent.
  • 5. The system of claim 1 wherein the mating interface is configured to leave an open space when the inner detent mates with the proximal cap.
  • 6. The system of claim 5 wherein the open space is defined by the mating interface and the proximal cap.
  • 7. The system of claim 5 wherein the mating interface is configured to allow at least a portion of the proximal cap to expand into the open space.
  • 8. The system of claim 5 wherein the open space is proximal to a distal end surface of the inner detent and facing the barb.
  • 9. The system of claim 1 wherein the mating interface includes a chamfered portion that defines an open space between the barb and the inner detent.
  • 10. The system of claim 1 wherein the barb is configured to cause the proximal cap to contract when not inserted within the inflation port.
  • 11. The system of claim 1 wherein the outer detent is configured to mate with a distal portion of the proximal cap.
  • 12. The system of claim 1 wherein the inner detent is at least partially within the outer detent.
  • 13. A system, comprising: an intragastric device including a proximal cap and an inflation port at the proximal cap; andan inflation device comprising— a tube extending from a proximal portion of the inflation device to a distal portion of the inflation device, the tube having a handle at the proximal portion and a barb at the distal portion, wherein the barb has a cross-sectional dimension greater than a cross-sectional dimension of the corresponding inflation port of the intragastric device;an inner detent over the barb, the inner detent having a mating interface; andan outer detent over the inner detent, the outer detent being configured to attach over the proximal cap of the intragastric device, wherein the tube is longitudinally advanceable relative to at least one of the inner and outer detents, andwherein a proximal portion of the proximal cap is configured to expand radially outward into engagement with the outer detent when the barb is inserted into the inflation port.
  • 14. The system of claim 13 wherein the mating interface includes a chamfered portion.
  • 15. The system of claim 14 wherein the chamfered portion is adjacent to the barb, and wherein the proximal cap and the chamfered portion define an open space adjacent to the barb.
  • 16. The system of claim 13 wherein a portion of the mating interface defines an open space when the inner detent mates with the proximal cap.
  • 17. The system of claim 13 wherein the tube is a first tube, the handle is a first handle, the barb is a first barb, the inflation port is a first inflation port, and wherein: the intragastric device further comprises a second inflation port, wherein the first and second inflation ports are fluidly connected to a first balloon and a second balloon, respectively, of the intragastric device; andthe inflation device comprises a second tube extending from the proximal portion of the inflation device to the distal portion of the inflation device, the second tube having a second handle at the proximal portion and a second barb at the distal portion, wherein the second barb has a cross-sectional dimension greater than a cross-sectional dimension of the second inflation port of the intragastric device.
CROSS-REFERENCE TO RELATED APPLICATION(S)

The present application is a U.S. National Phase application under 35 U.S.C. 371 of International Application Serial No. PCT/US2011/031463, filed Apr. 6, 2011, which claims the benefit of U.S. Provisional Patent Application Ser. No. 61/321,466, filed Apr. 6, 2010, the entire contents of which are incorporated herein by reference in their entireties. This application incorporates by reference in their entirety each of the following applications and publications: U.S. patent application Ser. No. 11/768,152, filed Jun. 25, 2007, entitled GASTRIC SPACE FILLER DEVICE, DELIVERY SYSTEM, AND RELATED METHODS; U.S. patent application Ser. No. 11/263,302, filed Oct. 31, 2005, entitled INTRAGASTRIC SPACE FILLER; U.S. Pat. Pub. No. 2007/0100367, published May 3, 2007, entitled INTRAGASTRIC SPACE FILLER; U.S. Pat. Pub. No. 2007/0100368, published May 3, 2007, entitled INTRAGASTRIC SPACE FILLER; U.S. Pat. Pub. No. 2007/0100369, published May 3, 2007, entitled INTRAGASTRIC SPACE FILLER; U.S. Pat. Pub. No. 2007/0149994, published Jun. 28, 2007, entitled INTRAGASTRIC SPACE FILLER AND METHODS OF MANUFACTURE; U.S. Pat. Pub. No. 2008/0243071, published Oct. 2, 2008, entitled INTRAGASTRIC BALLOON SYSTEM AND THERAPEUTIC PROCESSES AND PRODUCTS; U.S. Pat. Pub. No. 2008/0319471, published Dec. 25, 2008, entitled GASTRIC SPACE FILLER DEVICE, DELIVERY SYSTEM, AND RELATED METHODS; U.S. Pat. Pub. No. 2005/0159769, published Jul. 21, 2005, entitled BALLOON SYSTEM AND METHODS FOR TREATING OBESITY; U.S. Pat. Pub. No. 2009/0048624, published Feb. 19, 2009, entitled BALLOON SYSTEM AND METHODS FOR TREATING OBESITY; WIPO Pub. No. WO 2007/053556, published Oct. 5, 2007, entitled INTRAGASTRIC SPACE FILLER; WIPO Pub. No. WO 2007/053707, published Oct. 5, 2007, entitled INTRAGASTRIC SPACE FILLER; WIPO Pub. No. WO 2007/053706, published Oct. 5, 2007, entitled INTRAGASTRIC SPACE FILLER; and WIPO Pub. No. WO 2007/075810, published May 7, 2007, entitled INTRAGASTRIC SPACE FILLER.

PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2011/031463 4/6/2011 WO 00 2/4/2013
Publishing Document Publishing Date Country Kind
WO2011/127205 10/13/2011 WO A
US Referenced Citations (213)
Number Name Date Kind
1666690 Drevitson Apr 1928 A
1690995 Pratt Nov 1928 A
2493326 Trinder Jan 1950 A
2579301 Buntin Dec 1951 A
3131867 Miller et al. May 1964 A
4133315 Berman et al. Jan 1979 A
4198983 Becker et al. Apr 1980 A
4246893 Berson Jan 1981 A
4281582 Jaqua Aug 1981 A
4356824 Vazquez Nov 1982 A
4368739 Nelson, Jr. Jan 1983 A
4416267 Garren et al. Nov 1983 A
4436087 Ouchi et al. Mar 1984 A
4465072 Taheri Aug 1984 A
4465818 Shirahata et al. Aug 1984 A
4485805 Foster, Jr. Dec 1984 A
4543089 Moss Sep 1985 A
4598699 Garren et al. Jul 1986 A
4694827 Weiner et al. Sep 1987 A
4723547 Kullas et al. Feb 1988 A
4899747 Garren et al. Feb 1990 A
4940458 Cohn Jul 1990 A
5073347 Garren et al. Dec 1991 A
5084061 Gau et al. Jan 1992 A
5123840 Nates Jun 1992 A
5234454 Bangs Aug 1993 A
5259399 Brown Nov 1993 A
5263934 Haak Nov 1993 A
5273536 Savas Dec 1993 A
5318530 Nelson, Jr. Jun 1994 A
5334187 Fischell et al. Aug 1994 A
5431173 Chin et al. Jul 1995 A
5496271 Burton et al. Mar 1996 A
5516812 Chu et al. May 1996 A
5575772 Lennox Nov 1996 A
5639810 Smith, III et al. Jun 1997 A
5643209 Fugoso et al. Jul 1997 A
5730722 Wilk Mar 1998 A
5779728 Lunsford et al. Jul 1998 A
5857991 Grothoff et al. Jan 1999 A
5876376 Schwab et al. Mar 1999 A
5904701 Daneshvar May 1999 A
5938669 Klaiber et al. Aug 1999 A
5976073 Ouchi Nov 1999 A
5993473 Chan et al. Nov 1999 A
5997503 Willis et al. Dec 1999 A
6149621 Makihara Nov 2000 A
6179878 Duerig et al. Jan 2001 B1
6254355 Gharib Jul 2001 B1
6276567 Diaz et al. Aug 2001 B1
6280411 Lennox Aug 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6423058 Edwards et al. Jul 2002 B1
6427089 Knowlton Jul 2002 B1
6454785 De Hoyos Garza Sep 2002 B2
6524234 Ouchi Feb 2003 B2
6535764 Imran et al. Mar 2003 B2
6540789 Silverman et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6579301 Bales et al. Jun 2003 B1
6592552 Schmidt Jul 2003 B1
6613018 Bagga et al. Sep 2003 B2
6613037 Khosravi et al. Sep 2003 B2
6689051 Nakada Feb 2004 B2
6706010 Miki et al. Mar 2004 B1
6746460 Gannoe et al. Jun 2004 B2
6826428 Chen et al. Nov 2004 B1
6850128 Park Feb 2005 B2
6866627 Nozue et al. Mar 2005 B2
6866657 Shchervinsky Mar 2005 B2
6869431 Maguire et al. Mar 2005 B2
6890300 Lloyd et al. May 2005 B2
6890346 Ganz et al. May 2005 B2
6902535 Eberhart et al. Jun 2005 B2
6923754 Lubock Aug 2005 B2
6931286 Sigg et al. Aug 2005 B2
6939299 Petersen et al. Sep 2005 B1
6942680 Grayzel et al. Sep 2005 B2
6958052 Charlton Oct 2005 B1
7001419 DiCaprio et al. Feb 2006 B2
7016735 Imran et al. Mar 2006 B2
7020531 Colliou et al. Mar 2006 B1
7033373 de la Torre et al. Apr 2006 B2
7056305 Garza Alvarez Jun 2006 B2
7076305 Imran et al. Jul 2006 B2
7081125 Edwards et al. Jul 2006 B2
7131945 Fink et al. Nov 2006 B2
7483746 Lee et al. Jan 2009 B2
7625355 Yu Dec 2009 B2
7749254 Sobelman et al. Jul 2010 B2
7828749 Douglas et al. Nov 2010 B2
7829572 Didiuk et al. Nov 2010 B2
7931693 Binmoeller et al. Apr 2011 B2
8083757 Gannoe et al. Dec 2011 B2
8556925 Makower et al. Oct 2013 B2
8840952 Ashby et al. Sep 2014 B2
8894568 Pecor et al. Nov 2014 B2
9050174 Pecor et al. Jun 2015 B2
9149611 Bouasaysy Oct 2015 B2
20010022988 Schwarz et al. Sep 2001 A1
20010037127 De Hoyos Garza Nov 2001 A1
20020055757 Torre et al. May 2002 A1
20020107515 Edwards et al. Aug 2002 A1
20020161388 Samuels et al. Oct 2002 A1
20020173804 Rousseau Nov 2002 A1
20030105800 Cullen Jun 2003 A1
20030114878 Diederich et al. Jun 2003 A1
20030171768 McGhan Sep 2003 A1
20030187390 Bates et al. Oct 2003 A1
20040044354 Gannoe et al. Mar 2004 A1
20040059289 Garza Alvarez Mar 2004 A1
20040059290 Palasis Mar 2004 A1
20040073162 Bleam et al. Apr 2004 A1
20040087902 Richter May 2004 A1
20040093058 Cottone et al. May 2004 A1
20040106899 McMichael et al. Jun 2004 A1
20040116897 Aboul- Hosn Jun 2004 A1
20040127915 Fleenor et al. Jul 2004 A1
20040186502 Sampson et al. Sep 2004 A1
20040186503 DeLegge Sep 2004 A1
20040220665 Hossainy et al. Nov 2004 A1
20040236280 Rice et al. Nov 2004 A1
20040236361 Sakurai Nov 2004 A1
20040254600 Zarbatany et al. Dec 2004 A1
20050027283 Richard et al. Feb 2005 A1
20050027313 Shaker Feb 2005 A1
20050038415 Rohr et al. Feb 2005 A1
20050055039 Burnett et al. Mar 2005 A1
20050059990 Ayala et al. Mar 2005 A1
20050075624 Miesel Apr 2005 A1
20050085792 Gershowitz Apr 2005 A1
20050119674 Gingras Jun 2005 A1
20050131442 Yachia et al. Jun 2005 A1
20050143784 Imran Jun 2005 A1
20050159769 Alverdy Jul 2005 A1
20050177103 Hunter et al. Aug 2005 A1
20050192614 Binmoeller Sep 2005 A1
20050192615 Torre et al. Sep 2005 A1
20050228504 Demarais Oct 2005 A1
20050267595 Chen et al. Dec 2005 A1
20050267596 Chen et al. Dec 2005 A1
20050273060 Levy et al. Dec 2005 A1
20060058829 Sampson et al. Mar 2006 A1
20060142700 Sobelman et al. Jun 2006 A1
20060178691 Binmoeller Aug 2006 A1
20060184112 Horn et al. Aug 2006 A1
20060259020 Sharratt Nov 2006 A1
20060270906 Matsuno et al. Nov 2006 A1
20070016262 Gross et al. Jan 2007 A1
20070078476 Hull et al. Apr 2007 A1
20070083224 Hively Apr 2007 A1
20070093728 Douglas et al. Apr 2007 A1
20070100367 Quijano et al. May 2007 A1
20070100368 Quijano et al. May 2007 A1
20070100369 Cragg et al. May 2007 A1
20070118168 Lointier et al. May 2007 A1
20070135829 Paganon et al. Jun 2007 A1
20070142770 Rioux et al. Jun 2007 A1
20070149994 Sosnowski et al. Jun 2007 A1
20070173881 Birk et al. Jul 2007 A1
20070233161 Weller et al. Oct 2007 A1
20070250020 Kim et al. Oct 2007 A1
20070265369 Muratoglu et al. Nov 2007 A1
20070265598 Karasik Nov 2007 A1
20070288033 Murature et al. Dec 2007 A1
20080058887 Griffin et al. Mar 2008 A1
20080082056 Mauch et al. Apr 2008 A1
20080085887 Didiuk et al. Apr 2008 A1
20080097513 Kaji et al. Apr 2008 A1
20080119729 Copa et al. May 2008 A1
20080172079 Birk Jul 2008 A1
20080190363 Chen et al. Aug 2008 A1
20080208135 Annunziata et al. Aug 2008 A1
20080208241 Weiner et al. Aug 2008 A1
20080233167 Li et al. Sep 2008 A1
20080243071 Quijano et al. Oct 2008 A1
20080243166 Paganon et al. Oct 2008 A1
20080255601 Birk Oct 2008 A1
20080312679 Hardert et al. Dec 2008 A1
20080319471 Sosnowski et al. Dec 2008 A1
20090048624 Alverdy Feb 2009 A1
20090250236 Burnett et al. Oct 2009 A1
20090275973 Chen et al. Nov 2009 A1
20090287231 Brooks et al. Nov 2009 A1
20100023047 Simpson Jan 2010 A1
20100049224 Vargas Feb 2010 A1
20100063530 Valencon et al. Mar 2010 A1
20100130998 Alverdy May 2010 A1
20100174307 Birk Jul 2010 A1
20100191270 Garza et al. Jul 2010 A1
20100234853 Pecor et al. Sep 2010 A1
20100243135 Pepper et al. Sep 2010 A1
20100251837 Bouasaysy et al. Oct 2010 A1
20110172767 Rathi et al. Jul 2011 A1
20110178544 Sosnowski et al. Jul 2011 A1
20110276076 Paganon Nov 2011 A1
20110295300 Verd et al. Dec 2011 A1
20120191126 Pecor et al. Jul 2012 A1
20120271336 Hamman et al. Oct 2012 A1
20120271338 Bouasaysy et al. Oct 2012 A1
20120289992 Quijano et al. Nov 2012 A1
20130035710 Bouasaysy et al. Feb 2013 A1
20130053880 Bouasaysy et al. Feb 2013 A1
20130102876 Limon et al. Apr 2013 A1
20130261654 Bouasaysy et al. Oct 2013 A1
20130296914 Quijano et al. Nov 2013 A1
20140257358 Alverdy et al. Sep 2014 A1
20140371775 Ashby et al. Dec 2014 A1
20150216529 Kwok et al. Aug 2015 A1
20150238342 Sosnowski et al. Aug 2015 A1
20150265811 Pecor et al. Sep 2015 A1
20150366691 Bouasaysy et al. Dec 2015 A1
20160008156 Pecor et al. Jan 2016 A1
Foreign Referenced Citations (50)
Number Date Country
2638988 May 2007 CA
8708978 Nov 1987 DE
0103481 Mar 1984 EP
0457456 Nov 1991 EP
0485903 May 1992 EP
1781183 May 2007 EP
2862525 May 2005 FR
2892297 Apr 2007 FR
2090747 Jul 1982 GB
2139902 Nov 1984 GB
S57168674 Oct 1982 JP
S6415063 Jan 1989 JP
H091872 Apr 1989 JP
H08322943 Dec 1996 JP
2001128985 May 2001 JP
2006333888 Dec 2006 JP
2009285135 Dec 2009 JP
2015154964 Aug 2015 JP
2016127954 Jul 2016 JP
8805671 Aug 1988 WO
9000369 Jan 1990 WO
9925418 May 1999 WO
WO-0141700 Jun 2001 WO
WO-0166166 Sep 2001 WO
WO-0240081 May 2002 WO
2005082296 Sep 2005 WO
2005107641 Nov 2005 WO
2005120363 Dec 2005 WO
WO-2006035446 Apr 2006 WO
WO-2006056944 Jun 2006 WO
WO-2006128978 Dec 2006 WO
WO-2007027812 Mar 2007 WO
WO-2007053556 May 2007 WO
WO-2007053706 May 2007 WO
WO-2007053707 May 2007 WO
WO-2007075810 Jul 2007 WO
WO-2008042819 Apr 2008 WO
WO-2008121831 Oct 2008 WO
WO-2009055386 Apr 2009 WO
WO-2009112786 Sep 2009 WO
WO-2010048021 Apr 2010 WO
WO-2010115161 Oct 2010 WO
WO-2011011629 Jan 2011 WO
WO-2011011741 Jan 2011 WO
WO-2011011743 Jan 2011 WO
WO-2011024077 Mar 2011 WO
WO-2011038270 Mar 2011 WO
WO-2011097637 Aug 2011 WO
WO-2011127205 Oct 2011 WO
WO-2012048226 Apr 2012 WO
Non-Patent Literature Citations (88)
Entry
European Search Report—Supplementary; EP 03726447.0, Applicant: Applied Medical Resources Corporation: Mar. 1, 2006, 3 pgs.
Final Office Action; U.S. Appl. No. 11/694,536, Mailing Date Mar. 11, 2011, 13 pages.
Final Office Action; U.S. Appl. No. 11/768,152, Mailing Date Jan. 19, 2011, 13 pages.
International Search Report; International Application No. PCT/US2010/042948; Applicant: ReShape Medical, Inc., Mailing Date Apr. 1, 2011, 11 pages.
International Search Report; International Application No. PCT/US2010/043134; Applicant: ReShape Medical, Inc., Mailing Date Apr. 27, 2011, 12 pages.
International Search Report; International Application No. PCT/US2010/043136; Applicant: ReShape Medical, Inc., Mailing Date Apr. 12, 2011, 9 pages.
International Search Report; International Application No. PCT/US2010/050260; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 17, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/026233; Applicant: ReShape Medical, Inc., Mailing Date Apr. 26, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/031463; Applicant: ReShape Medical, Inc., Mailing Date: Jun. 27, 2011, 10 pages.
International Search Report; International Application No. PCT/US2003/012782, Applicant: Applied Medical Resources Corporation, dated: Oct. 28, 2003, 7 pages.
International Search Report; International Application No. PCT/US2006/042336, Applicant: Abdominus, Inc., dated: Mar. 14, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/042710, Applicant: Abdominus, Inc. et al., dated: Mar. 15, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/042711, Applicant: Abdominus, Inc. et al, dated: Mar. 16, 2007, 9 pages.
International Search Report; International Application No. PCT/US2006/048647, Applicant: Abdominus, Inc. et al., dated: May 22, 2007, 12 pages.
International Search Report; International Application No. PCT/US2008/058677, Applicant: ReShape Medical et al., dated: Aug. 21, 2008, 12 pages.
International Search Report; International Application No. PCT/US2008/068058, Applicant: ReShape Medical, Inc. et al, dated: Nov. 19, 2008, 11 pages.
International Searbh Report; International Application No. PCT/US2010/029865, Applicant: ReShape Medical, Inc., dated: Jan. 5, 2011, 9 pages.
International Search Report; International Application No. PCT/US2011/024077; Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 12 pages.
International Search Report; International Application No. PCT/US2011/024082, Applicant: ReShape Medical, Inc., dated: Apr. 6, 2011, 10 pages.
International Search Report; International Application No. PCT/US1155373, Applicant: Reshape Medical, Inc., dated: Jan. 20, 2012, 7 pages.
“Living with the BIB: BioEnterics Intragastric Balloon Program: Patient Information”; INAMED Health: Bioenteris Corporation, ECO-SBA-10434; dated Apr. 20, 2004 and May 14, 2005, located online at: www.sydneyobesity.com.au/pdf/M946-01.pdf; 10 pages.
Non-Final Office Action; U.S. Appl. No. 11/263,302; dated: Oct. 9, 2012, 6 pages.
Non-Final Office Action; U.S. Appl. No. 11/694,536; dated: Oct. 26, 2011, 13 pages.
Non-Final Office Action; U.S. Appl. No. 12/723,545; dated Feb. 29, 2012, 10 pages.
Non-Final Office Action; U.S. Appl. No. 12/625,473; dated Oct. 24, 2011, 18 pages.
Non-Final Office Action; U.S. Appl. No. 12/625,473; dated Jul. 12, 2012; 10 pages.
Non-Final Office Action; U.S. Appl. No. 12/753,751; dated Oct. 5, 2012, 8 pages.
Non-Final Office Action; U.S. Appl. No. 13/074,956; dated Oct. 1, 2012, 8pages.
ReShape Inflatable Gastric Balloon Going on Trial as Weight Loss Option, MedGadget: Internet Journal of Emerging Medical Technologies. Feb. 4, 2010, 5 pages.
Wahlen CH et al. “The BioEnterics Intragastric Balloon: How to use it” Obesity Surgery 2001; 11:524-527.
Extended European Search Report; Application No. EP11748141.6, Applicant: Reshape Medical, Inc., mailed Feb. 25, 2014, 6 pages.
Final Office Action; U.S. Appl. No. 13/858,767, Mailing Date May 22, 2103, 12 pages.
Extended European Search Report; Application EP11740536.5, Applicant: ReShape Medical, Inc., mailed Jul. 3, 2014, 8 pages.
Extended European Search Report; Application EP11831683.5, Applicant: Reshape Medical, Inc., mailed Jul. 3, 2014, 8 pages.
Final Office Action; U.S. Appl. No. 13/556,8-32, mailed on Jan. 28, 2014, 8 pages.
Non-Final Office Action; U.S. Appl. No. 13/386,650; mailed on Jun. 3, 2014, 15 pages.
Notice of Allowance; U.S. Appl. No. 12/753,803, dated May 13, 2014, 18 pages.
Ostrovsky, ReShape Inflatable Gastric Balloon going on Trial as Weight Loss Option; http://www.medgadget.com/2010/02/reshape—inflatable—gastric—balloon—system—going—on—trial—as—wieight—loss—option.html Feb. 4, 2010, retrieved on Feb. 10-2-13.
European Supplementary Search Report; EP Application No. 10802994.3, Applicant: ReShape Medical, Inc., mailed Jun. 28, 2013, 8 pgs.
European Supplementary Search Report; EP Application No. 10802918.2, Applicant: ReShape Medical, Inc., mailed Jun. 5, 2013, 6 pgs.
Extended European Search Report; Application No. EP6827098.3, Applicant: Reshape Medical, Corporation, mailed on Aug. 25, 2014, 3 pages.
Extended European Search Report; Application No. EP6827314.3, Applicant: ReShape Medical Corporation, mailed on Aug. 1, 2014, 3 pages.
Extended European Search Report; Application No. EP6827313.5, Applicant: ReShape Medical Corporation, mailed on Jul. 30, 2014, 5 pages.
Extended European Search Report; Application No. EP6847847.8, Applicant: ReShape Medical Corporation, mailed on Aug. 14, 2014, 5 pages.
Final Office Action; U.S. Appl. No. 13/858,767, mailed on May 30, 2014, 12 pages.
Non-Final Office Action; U.S. Appl. No. 13/386,638, mailed on Jun. 27, 2014, 12 pages.
Extended European Search Report; Application No. EP11766679.2, Applicant Reshape Medical, Inc., mailed Dec. 12, 2013, 6 pages.
Cronin, Carmel G. et al., “Normal small bowel wall characteristics on MR enterography,” European Journal of Radiology 74(2):207-211, Aug. 2010.
Gray, Henry, Anatomy of the Human Body. Philadelphia: Lea & Febiger, 1918. Section XI Splanchnology, 2g. The Small Intestine. Bartleby.com, 2000. Web. URL: www.bartleby.com/107/248.html. Accessed: Oct. 26, 2015. 12 pages.
Partial Supplementary European Search Report for European Application No. 11740535.7, Applicant: ReShape Medical, Inc., mailed Oct. 20, 2015, 7 pages.
Final Office Action for Japanese Application No. 2014-52972, Applicant: ReShape Medical, Inc., mailed on Oct. 9, 2015, 8 pages.
Canadian Office Action; Application No. CA 2638163, Applicant: Reshape Medical, Inc., mailed Dec. 8, 2015, 4 pages.
Canadian 2nd Office Action Application No. 2680124, Applicant: ReShape Medical, Inc., mailed Jul. 9, 2015, 3 pages.
European Examination Report; Application No. 06827313.5, Applicant: ReShape Medical Inc., mailed Jul. 13, 2015, 5 pages.
European Examination Report; Application No. 06847847.8, Applicant: ReShape Medical Inc., mailed Jul. 13, 2015, 4 pages.
Japanese Office Action; Application No. 2013-532976; Applicant: ReShape Medical, Inc., mailed Jun. 26, 2015, 10 pages.
Canadian Office Action: Application No. CA 2680124, Applicant: Reshape Medical Corporation, mailed Nov. 4, 2014, 3 pages.
Canadian Office Action; Application No. 2,691,530, mailed Dec. 18, 2014, 4 pages.
Canadian Office Action; Application No. CA 2638163, Applicant: Reshape Medical Corporation, mailed Mar. 10, 2015, 4 pages.
Canadian Office Action; Application No. CA 2638988, Applicant Reshape Medical Corporation, mailed Dec. 22, 2014 3 pages.
Canadian Office Action; Application No. CA 2638988, Applicant Reshape Medical Corporation, mailed Mar. 6, 2014, 4 pages.
Canadian Office Action; Application No. CA 2638989, Applicant: Reshape Medical Corporation, mailed May 22, 2013 3 pages.
Canadian Office Action; Application No. CA 2640554, Applicant: Reshape Medical Corporation, mailed May 27, 2013, 2 pages.
Canadian Office Action; Application No. CA2484838, Applicant: Reshape Medical, Inc., mailed Nov. 13, 2009, 3 pages.
Canadian Office Action; Application No. CA2484838, Applicant: Reshape Medical, Inc., mailed Sep. 24, 2010, 3 pages.
Canadian Office Action; Application No. CA2638163, Applicant: Reshape Medical Corporation, mailed Jul. 17, 2013, 2 pages.
Canadian Office Action; Application No. CA2638988, Applicant: Reshape Medical Corporation, mailed May 28, 2013, 3 pages.
Canadian Office Action; Application No. CA2780085, Applicant: Reshape Medical, Inc., mailed Jul. 23, 2012, 2 pages.
European Examination Report; Application No. 03726447.0, Applicant: Applied Medical Resources Corporation: Oct. 26, 2007, 4 pages.
European Examination Report; Application No. EP108002918.2, Applicant: Reshape Medical Inc., mailed Dec. 17, 2014, 5 pages.
European Examination Report; Application No. EP108029943, Applicant: Reshape Medical Inc., mailed Dec. 18, 2014, 4 pages.
European Examination Reported; Application No. 08771842.5, May 7, 2015, 5 pages.
European Supplementary Search Report; Application No. 08771842.5, Apr. 24, 2015, 3 pages.
Extended European Search Report; Application No. 08732989.2, Applicant: Reshape Medical, Inc., mailed Oct. 16, 2014, 7 pages.
Japanese Final Office Action; Application No. JP2013-043712, mailed Nov. 15, 2013, 5 pages.
Japanese Office Action; Application No. 2013-142327, mailed May 29, 2014, 4 pages.
Japanese Office Action; Application No. 2014-52972; mailed Feb. 25, 2015, 7 pages.
Japanese Office Action; Application No. JP2010-501261, mailed Sep. 7, 2012, 10 pages.
Japanese Office Action; Application No. JP2010-515040, mailed Jan. 7, 2013, 18 pages.
Japanese Office Action; Application No. JP2012-503759, mailed Mar. 24, 2014, 5 pages.
Japanese Office Action; Application No. JP2013-43712, mailed Jan. 8, 2015, 8 pages.
Japanese Office Action; Application. No. JP2013-043712, mailed Apr. 22, 2013, 5 pages.
Chou, Chyuan et al., “Structural Effects On The Thermal Properties Of PDPS/PDMS Copolymers,” Journal of Thermal Analysis, vol. 40, pp. 657-667, 1993.
European Search Report for European Application No. 11740535.7, Applicant: ReShape Medical, Inc., mailed Mar. 8, 2016, 14 pages.
Extended European Search Report; Application No. 15198773.2, Application ReShape Medical Corporation, mailed Jul. 15, 2016, 7 pages.
European Examination Report; Application No. 11766679.2, Applicant: Reshape Medical Inc., mailed Dec. 1, 2016, 4 pages.
European Examination Report; Application No. 11748141.6, Applicant: Reshape Medical Inc., mailed Dec. 8, 2016, 3 pages.
Extended European Search Report; Application No. 16183882.6, Applicant: Reshape Medical Inc., mailed Feb. 17, 2017, 9 pages.
Related Publications (1)
Number Date Country
20140031850 A1 Jan 2014 US
Provisional Applications (1)
Number Date Country
61321466 Apr 2010 US